Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma

Journal of Pathology

Volumn 178, Issue 1, 1996, Pages 53-58

  Dalquen, Peter ^a   Sauter, Guido ^a   Torhorst, Joachim ^a   Schultheiss, Elisabeth ^a   Jordan, Paul ^a   Lehmann, Stephan ^a   Solèr, Marcus ^a   Stulz, Peter ^b   Mihatsch, Michael J ^a   Gudat, Fred ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Immunohistochemistry; Non small cell lung carcinoma; p53; Prognosis; Survival

Indexed keywords

PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13244300654     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199601)178:1<53::AID-PATH415>3.0.CO;2-T     Document Type: Article

References (41)

1. Dillman RO, Berry C, Ryan KP, Green MR, Seagren SL Recent outcomes for patients with carcinoma of the lung. Cancer Invest 1991; 9: 9 17.
2. Mountain CF. Surgical treatment of lung cancer. Rev Oncoll Hematol 1991; 11: 179-207.
3. Hasse J. Surgical Treatment of Bronchial Carcinoma, Screening Methods, Early and Late Results. Berlin, Springer-Verlag, 1986, 158
4. Lane D p53, guardian of the genome. Nature 1992; 358: 15-16.
5. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-915.
6. Thor AD, Yandell DW. Prognostic significance of p53 overexpression in node-negative breast carcinomas: preliminary studies support cautious optimism J Natl Cancer Inst 1993; 85: 176-177
7. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas denned by p53 accumulation. J Natl Cancer Inst 1992; 84: 883-887.
8. Sarkis AS, Zhang ZF, Cordon CC, et al. p53 Nuclear overexpression and disease progression in Ta bladder carcinoma Int J Oncol 1993; 3: 355-360.
9. Iggo R, Gatter KC, Bartek J, Lane DP, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679
10. McLaren R, Kuzu I, Dunnill M, Harris A, Lane DP, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992, 66: 735-738.
11. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-4831.
12. Brambilla E, Gazzeri S, Moro D, et al Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993; 143: 199-210.
13. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994; 54: 2496-2503.
14. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993, 53: 1-4
15. Chiba I, Takahashi T, Nau MM, et al. Mutations m the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990; 5: 1603-1610.
16. Caamano J, Ruggeri B, Momiki S, Sickler A, Zhang SY, Klein SAJ. Detection of p53 in primary lung tumors and non-small cell lung carcinoma cell lines. Am J Pathol 1991; 139: 839-845.
17. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992; 52: 4799-4804.
18. Mitsudomi T, Steinberg SM, Nau MM, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171-180.
19. Soini Y, Kamel D, Nuorva K, Lane DP, Dähäkangas K, Pääkö P Low p53 protein expression in salivary gland tumors compared with lung carcinomas. Virchows Arch A 1992; 421: 415-420.
20. Korkolopoulou P, Oates J, Crocker J, Edwards C. p53 expression in oat and non-oat small cell lung carcinomas; correlations with proliferating cell nuclear antigen. J Clin Pathol 1993; 46: 1093-1096.
21. Marchetti A, Buttitta F, Merlo G, et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes Cancer Res 1993; 53: 2846-2851.
22. Westra WH, Offerhaus GJA, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993, 17: 213-220.
23. Hermanek P, Scheibe O, Spiessl B, Wagner G. TNM Klassifikation maligner Tumoren Berlin: Springer-Verlag, 1992-80-82.
24. The World Health Organization. Histologic Typing of Lung Cancer Geneva: WHO, 1981: 89: 1595-1602
25. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A 1993; 423: 329 334.
26. Hollstein M, Sidransky D, Vogelstein B, Harris CC p53 mutations in human cancers. Science 1991; 253: 49-53.
27. Levine AJ, Momand J, Finlay CA The p53 tumor suppressor gene Nature 1991; 351: 453-456.
28. Harris CC, Hollstein M, Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327.
29. Hall PA, Lane DP. p53 in tumour pathology can we trust immunocytochemistry? - revisited! J Pathol 1994; 172: 1-4.
30. Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-539.
31. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4: 1689-1694.
32. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859-862
33. Baas I, Mulder J, Offerhaus J, Vogelstein B, Hamilton S. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 13-18.
34. Bodner SM, Minna JD, Jensen SM, et al Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7: 743-749
35. Suzuki H, Takahashi T, Kuroishi T, et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking Cancer Res 1992; 52: 734-736
36. Ryberg D, Kure E, Lystad S, et al. p53 mutations in lung tumors, relationship to putative susceptibility markers for cancer. Cancer Res 1994; 54: 1551-1555
37. Shields TW. Classification and prognosis of surgically treated patients with bronchial carcinoma: analysis of VASOG studies. Int J Radiation Oncol Biol Phys 1980, 6: 1021-1027.
38. Tosi P, Luzi P, Leoncini L, Miracco C, Gambacorta M, Grossi A. Survival after surgical treatment according to stage, histologic type and immunomorphologic changes in regional lymph nodes Cancer 1981; 48: 2288-2295.
39. Temeck BK, Flehinger BJ, Martini N. A retrospective analysis of 10-year survivors from carcinoma of the lung Cancer 1984, 53: 1405-1408
40. Kayser KW, Heinrich S, Toomes H, Klimek M. Prognostic factors of bronchogenic carcinoma patients: clinical and post-operative staging, histological grading. Tumor Diagn Ther 1985; 6: 149-154.
41. Kakeji Y, Korenaga D, Tsujitani S, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes Br J Cancer 1993; 67: 589-593.